TropIQ receives price for Dutch innovative startup By Monique06/12/201614/04/2017 Categories: News TropIQ receives the Unilever Sustainable Innovation Prize for the Dutch innovative startup best contributing to the Sustainable Development Goals as put forward by the United Nations.
Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. By Monique20/10/201620/04/2017 Categories: Publications Kato N, et. al., Nature. 2016 Oct 20 ABSTRACT Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate…
TropIQ staff co-authors publication on novel antimalarial compound By Monique04/10/201619/04/2017 Categories: News October 4, 2016. TropIQ staff co-author the study ‘Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling’ published in PloS Medicine today.
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. By Monique04/10/201619/04/2017 Categories: Publications Artemisinin resistance observed in Southeast Asia threatens the continued use of artemisinin-based combination therapy in endemic countries.
TropIQ is awarded with a ‘Pearl of the region’ By Monique15/09/201606/03/2017 Categories: News TropIQ is awarded with a ‘Pearl of the region’ award by The Economic Board. Waarom roept The Economic Board ‘parels van de regio’ in het leven? De Board…
TropIQ staff co-authors paper in Nature By Monique07/09/201606/03/2017 Categories: News Nature publishes the paper ‘Diversity-oriented synthesis yields novel multistage antimalarial inhibitors’ that is co-authored by TropIQ staff. Antimalarial drugs have thus far beenchiefly derived from two sources—natural products…